Publication:
Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients".

Simple item page
dc.contributor.authorRodriguez-Peralvarez, Manuel
dc.contributor.authorColmenero, Jordi
dc.contributor.authorSalcedo, Magdalena
dc.contributor.groupSpanish Society of Liver Transplantation (SETH)
dc.date.accessioned2023-02-09T10:52:20Z
dc.date.available2023-02-09T10:52:20Z
dc.date.issued2021-04-03
dc.description.abstractWe read with great interest the letter by G. J. Webb et al. regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease 2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (COVID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors influencing outcomes. We completely agree with this conclusion, which may also be true for non-transplant patients with COVID19. However, some statements require further clarification.
dc.description.versionSi
dc.identifier.citationRodríguez-Perálvarez M, Colmenero J, Salcedo M; Spanish Society of Liver Transplantation (SETH). Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients". J Hepatol. 2021 Jul;75(1):228-229
dc.identifier.doi10.1016/j.jhep.2021.04.005
dc.identifier.essn1600-0641
dc.identifier.pmcPMC8056821
dc.identifier.pmid33862040
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056821/pdf
dc.identifier.unpaywallURLhttp://www.journal-of-hepatology.eu/article/S0168827821002397/pdf
dc.identifier.urihttp://hdl.handle.net/10668/17590
dc.issue.number1
dc.journal.titleJournal of hepatology
dc.journal.titleabbreviationJ Hepatol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number228-229
dc.provenanceRealizada la curación de contenido 14/08/2024
dc.publisherElsevier
dc.pubmedtypeLetter
dc.pubmedtypeComment
dc.relation.publisherversionhttps://www.journal-of-hepatology.eu/article/S0168-8278(21)00239-7/fulltext
dc.rights.accessRightsopen access
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectCalcineurin inhibitors
dc.subjectEverolimus
dc.subjectImmunosuppression
dc.subjectMycophenolate
dc.subjectPneumonia
dc.subjectTacrolimus
dc.subjectTransplantation
dc.subject.decsComorbilidad
dc.subject.decsInhibidores de la calcineurina
dc.subject.decsInmunosupresores
dc.subject.decsTrasplante de hígado
dc.subject.meshCOVID-19
dc.subject.meshCalcineurin inhibitors
dc.subject.meshComorbidity
dc.subject.meshHumans
dc.subject.meshImmunosuppressive agents
dc.subject.meshLiver transplantation
dc.subject.meshSARS-CoV-2
dc.titleReply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients".
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number75
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
PMC8056821.pdf
Size:
228.5 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
Rodriguez-Peralvarez_ReplyTo_MaterialSuplementario.pdf
Size:
171.24 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Reina Sofía
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía